daclizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
human origin	4953	152923-56-3

Description:

Molecule	Description
Synonyms: zinbryta daclizumab zenapax	An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

zinbryta
daclizumab
zenapax

An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
5	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Feb. 26, 1999	EMA
Dec. 10, 1997	FDA	HOFFMAN-LA ROCHE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Transplant dysfunction	2367.98	49.14	405	4454	4279	50595986
Transplant rejection	1899.59	49.14	376	4483	9233	50591032
Ovarian cyst	1690.22	49.14	364	4495	13632	50586633
Acne	1584.27	49.14	367	4492	19228	50581037
Alopecia	824.77	49.14	418	4441	244629	50355636
Sleep disorder due to general medical condition, insomnia type	417.61	49.14	144	4715	31303	50568962
Liver function test abnormal	394.36	49.14	151	4708	44188	50556077
Multiple sclerosis relapse	259.77	49.14	111	4748	42853	50557412
Rheumatoid arthritis	183.90	49.14	153	4706	202397	50397868
Pneumonia	138.46	49.14	175	4684	378226	50222039
Condition aggravated	134.14	49.14	153	4706	296905	50303360
Loss of personal independence in daily activities	120.41	49.14	78	4781	69972	50530293
Incorrect route of product administration	95.61	49.14	43	4816	18623	50581642
Overdose	91.47	49.14	76	4783	99651	50500614
Kidney transplant rejection	84.13	49.14	26	4833	3961	50596304
Pain	79.30	49.14	172	4687	578731	50021534
Product use issue	67.11	49.14	77	4782	149398	50450867

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	149.72	36.32	36	521	11383	29562587

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Transplant dysfunction	2330.09	49.09	408	4579	6300	64487445
Ovarian cyst	1861.45	49.09	365	4622	10653	64483092
Transplant rejection	1740.63	49.09	373	4614	17028	64476717
Acne	1603.20	49.09	367	4620	22714	64471031
Alopecia	1061.45	49.09	416	4571	165274	64328471
Sleep disorder due to general medical condition, insomnia type	473.69	49.09	144	4843	26126	64467619
Liver function test abnormal	386.70	49.09	152	4835	59249	64434496
Multiple sclerosis relapse	298.45	49.09	114	4873	41021	64452724
Rheumatoid arthritis	239.94	49.09	152	4835	164142	64329603
Condition aggravated	138.02	49.09	156	4831	372270	64121475
Loss of personal independence in daily activities	133.55	49.09	78	4909	72376	64421369
Pneumonia	118.89	49.09	178	4809	559398	63934347
Pain	106.14	49.09	168	4819	553343	63940402
Incorrect route of product administration	95.40	49.09	43	4944	23255	64470490
Product use issue	85.79	49.09	80	4907	151635	64342110
Overdose	82.35	49.09	80	4907	159486	64334259
Drug ineffective	64.61	49.09	175	4812	840072	63653673
Encephalitis autoimmune	50.08	49.09	14	4973	1870	64491875

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AC01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors
FDA MoA	N0000010279	Interleukin 2 Receptor Antagonists
MeSH PA	D007155	Immunologic Factors
MeSH PA	D007166	Immunosuppressive Agents
FDA MoA	N0000175621	Interleukin 2 Receptor-directed Antibody Interactions
FDA EPC	N0000175622	Interleukin-2 Receptor Blocking Antibody

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Renal transplant rejection	indication	236570004
Relapsing remitting multiple sclerosis	indication	426373005	DOID:2378

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-2 receptor	Membrane receptor	P01589 P14784 P31785	IL2RA_HUMAN IL2RB_HUMAN IL2RG_HUMAN	ANTIBODY BINDING	Kd	8		IUPHAR	DRUG LABEL

External reference:

ID	Source
D03639	KEGG_DRUG
4021083	VUID
N0000148541	NUI
4021083	VANDF
CHEMBL1201605	ChEMBL_ID
6880	IUPHAR_LIGAND_ID
7164	INN_ID
DB00111	DRUGBANK_ID
CUJ2MVI71Y	UNII
1795335	RXNORM
11508	MMSL
241453	MMSL
4529	MMSL
d04262	MMSL
109133001	SNOMEDCT_US
386977009	SNOMEDCT_US
D000077561	MESH_DESCRIPTOR_UI
C0663182	UMLSCUI
007284	NDDF

Pharmaceutical products:

None